This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Khan, A. A. Articles by Syed, Z. A. Search for Related Content PubMed PubMed Citation Articles by Khan, A. A. Articles by Syed, Z. A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Alendronate in Primary Hyperparathyroidism: A Double-Blind, Randomized, Placebo-Controlled Trial

Department of Medicine (A.A.K., M.M.A., S.J.D., A.M.S., T.I.S., Z.S., Z.A.S.), McMaster University, Hamilton, Ontario, Canada L6J 1X8; Departments of Medicine (J.P.B., D.S., M.R.R., S.J.S.) and Pharmacology (J.P.B.), College of Physicians and Surgeons, Columbia University, New York, New York 10032; and Department of Medicine (A.W.C.K., A.Y.Y.H.), Queen Mary Hospital, University of Hong Kong, Hong Kong, China

Address all correspondence and requests for reprints to: Aliya Khan, M.D., FRCPC, FACP, McMaster University, 331-209 Sheddon Avenue, Oakville, Ontario, Canada L6J 1X8. E-mail: avkhan{at}aol.com.

Primary hyperparathyroidism (PHPT) is often associated with reduced bone mineral density (BMD). A randomized, double-blind, placebo-controlled trial was conducted to determine whether alendronate (ALN), 10 mg daily, maintains or improves BMD in patients with PHPT. Eligible patients had asymptomatic PHPT and did not meet surgical guidelines or refused surgery. Forty-four patients randomized to placebo or active treatment arms were stratified for gender. At 12 months, patients taking placebo crossed over to active treatment. All patients were on active treatment in yr 2. The primary outcome index, BMD, at the lumbar spine (LS), femoral neck, total hip, and distal one third radius was measured every 6 months by dual-energy x-ray absorptiometry. Calcium, phosphorous, PTH, bone-specific alkaline phosphatase (BSAP) activity, urinary calcium, and urinary N-telopeptide (NTX) excretion were monitored every 3 months. Treatment with alendronate over 2 yr was associated with a significant (6.85%; µ_d = 0.052; ±0.94% SE; P < 0.001) increase in LS BMD in comparison with baseline. Total hip BMD increased significantly at 12 months with alendronate by 4.01% (µ_d = 0.027; ±0.77% SE; P < 0.001) from baseline and remained stable over the next 12 months of therapy. BMD at the one third radius site did not show any statistically significant change in the alendronate-treated group at 12 or 24 months of therapy. At 24 months, the alendronate-treated group showed a 3.67% (µ_d = 0.022; ±1.63% SE; P = 0.038) gain in bone density at the femoral neck site in comparison with baseline. The placebo group, when crossed over to alendronate at 12 months, showed a significant change of 4.1% (µ_d = 0.034; ±1.12% SE; P = 0.003) in the LS BMD and 1.7% (µ_d = 0.012; ±0.81% SE; P = 0.009) at the total hip site in comparison with baseline. There was no statistically significant change seen in the placebo group at 12 months at any BMD site and no significant change at 24 months for the distal one third radius or femoral neck sites. Alendronate was associated with marked reductions in bone turnover markers with rapid decreases in urinary NTX excretion by 66% (µ_d = –60.27; ±13.5% SE; P < 0.001) at 3 months and decreases in BSAP by 49% at 6 months (µ_d = –15.98; ±6.32% SE; P < 0.001) and by 53% at 9 and 12 months (µ_d = –17.11; ±7.85% SE; P < 0.001; µ_d = –17.36; ±6.96% SE; P < 0.001, respectively) of therapy. In the placebo group, NTX and BSAP levels remained elevated. Serum calcium (total and ionized), PTH, and urine calcium did not change with alendronate therapy. In PHPT, alendronate significantly increases BMD at the LS at 12 and 24 months from baseline values. Significant reductions in bone turnover occur with stable serum calcium and PTH levels. Alendronate may be a useful alternative to parathyroidectomy in asymptomatic PHPT among those with low BMD.

This work was supported in part by the Merck Medical School Grants Program and National Institutes of Health Grant DK32333.

Abbreviations: BMD, Bone mineral density; BSAP, bone-specific alkaline phosphatase; NTX, N-telopeptide; PHPT, primary hyperparathyroidism.

This article has been cited by other articles:

				C. Marcocci, P. Chanson, D. Shoback, J. Bilezikian, L. Fernandez-Cruz, J. Orgiazzi, C. Henzen, S. Cheng, L. R. Sterling, J. Lu, et al. Cinacalcet Reduces Serum Calcium Concentrations in Patients with Intractable Primary Hyperparathyroidism J. Clin. Endocrinol. Metab., August 1, 2009; 94(8): 2766 - 2772. [Abstract] [Full Text] [PDF]

				A. Khan, A. Grey, and D. Shoback Medical Management of Asymptomatic Primary Hyperparathyroidism: Proceedings of the Third International Workshop J. Clin. Endocrinol. Metab., February 1, 2009; 94(2): 373 - 381. [Abstract] [Full Text] [PDF]

				P Iglesias and J J Diez Current treatments in the management of patients with primary hyperparathyroidism Postgrad. Med. J., January 1, 2009; 85(999): 15 - 23. [Abstract] [Full Text] [PDF]

				N. Farag, T. Delbanco, and G. J. Strewler Update: A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, November 5, 2008; 300(17): 2044 - 2045. [Full Text] [PDF]

				F. R. SINGER and D. R. EYRE Using biochemical markers of bone turnover in clinical practice Cleveland Clinic Journal of Medicine, October 1, 2008; 75(10): 739 - 750. [Abstract] [Full Text] [PDF]

				E. Ambrogini, F. Cetani, L. Cianferotti, E. Vignali, C. Banti, G. Viccica, A. Oppo, P. Miccoli, P. Berti, J. P. Bilezikian, et al. Surgery or Surveillance for Mild Asymptomatic Primary Hyperparathyroidism: A Prospective, Randomized Clinical Trial J. Clin. Endocrinol. Metab., August 1, 2007; 92(8): 3114 - 3121. [Abstract] [Full Text] [PDF]

				B. Farford, R. J. Presutti, and T. J. Moraghan Nonsurgical Management of Primary Hyperparathyroidism Mayo Clin. Proc., March 1, 2007; 82(3): 351 - 355. [Abstract] [Full Text] [PDF]

				L. H. VanderWalde, I.-L. A. Liu, T. X. O'Connell, and P. I. Haigh The Effect of Parathyroidectomy on Bone Fracture Risk in Patients With Primary Hyperparathyroidism Arch Surg, September 1, 2006; 141(9): 885 - 891. [Abstract] [Full Text] [PDF]

				H. Ohlrich, K. Barco, and M. R. Silver The Use of Parenteral Nutrition in a Severely Malnourished Hemodialysis Patient With Hypercalcemia Nutr Clin Pract, October 1, 2005; 20(5): 559 - 568. [Abstract] [Full Text] [PDF]

				E. M. Brown Medical Therapy of Primary Hyperparathyroidism: Are We There Yet? IBMS BoneKEy, August 1, 2005; 2(8): 5 - 8. [Full Text] [PDF]

				G. J. Strewler A 64-Year-Old Woman With Primary Hyperparathyroidism JAMA, April 13, 2005; 293(14): 1772 - 1779. [Full Text] [PDF]

				L. A. Lambert, S. E. Shapiro, J. E. Lee, N. D. Perrier, M. Truong, M. J. Wallace, A. O. Hoff, R. F. Gagel, and D. B. Evans Surgical Treatment of Hyperparathyroidism in Patients With Multiple Endocrine Neoplasia Type 1 Arch Surg, April 1, 2005; 140(4): 374 - 382. [Abstract] [Full Text] [PDF]